EUVIMEDEUVIMED entdecken
Open Access

Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies

Ahmed Abdelhakeem, Hani M Babiker iD

Annals of Pancreatic Cancer · 2026-08 · 9 · 21-21

DOI: 10.21037/apc-26-0014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pancreatic Cancer, 2026-08. Verfasst von Ahmed Abdelhakeem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

administration achieved an mOS of 14 months compared to 8.8 months in low expanders

Schlagwörter

Stichwörter der Autor:innen

CD40 agonistbiomarkersimmunotherapymitazalimabpancreatic cancer

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.

ORCID-Profile: Hani M Babiker

Förderung

  • NCI NIH HHS

Zitieren

APA

Abdelhakeem, A., & Babiker, H. M. (2026). Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies. Annals of Pancreatic Cancer, 9, 21-21. https://doi.org/10.21037/apc-26-0014

Vancouver

Abdelhakeem A, Babiker HM. Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies. Annals of Pancreatic Cancer. 2026;9:21-21. doi:10.21037/apc-26-0014

BibTeX
@article{Abdelhakeem2026,
  author = {Abdelhakeem, Ahmed and Babiker, Hani M},
  title = {Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies},
  journal = {Annals of Pancreatic Cancer},
  year = {2026},
  volume = {9},
  pages = {21--21},
  doi = {10.21037/apc-26-0014}
}
Kostenlos starten →